Chinook Therapeutics CVR
13F holders, Q3 2024 (September 30)4holders
0new positions
1sold out
$0.27avg. 13F price*
At the end of Q3 2024, 4 institutions reported holding Chinook Therapeutics CVR in their 13F filings, unchanged from Q2 2024. 0 opened new positions and 1 sold out. The largest holders were Erste Asset Management GmbH ($120K), Propel Bio Management, LLC ($10K) and Rhumbline Advisers ($0).
- Company
- Chinook Therapeutics CVR
- CUSIP
- 169CVR016
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 60,000 shares sold, net −60,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Erste Asset Management GmbH | 0.00% | No change | 307,769 | $120K |
| Propel Bio Management, LLC | 0.01% | No change | 79,357 | $10K |
| Rhumbline Advisers | 0.00% | No change | 89,419 | $0 |
| Sterling Capital Management LLC | 0.00% | — | 1,053 | $0 |
"% of holder's portfolio" is CHINOOK THERAPEUTICS CVR's weight in each manager's 13F, not the share of Chinook Therapeutics CVR the manager owns.